What changed: Recurrent or metastatic cervical cancer
Every dated change on the records linked to Recurrent or metastatic cervical cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Regulatory1Trial result6Milestone6This record1
September 2026 · 1
2024 · 2
2023 · 4
- 2023Trial resultBEATcc / ENGOT-Cx10 / GOG-3030BEATcc / ENGOT-Cx10 / GOG-3030 reported
OS 32.
- 2023Trial resultDESTINY-PanTumor02DESTINY-PanTumor02 reported
Endometrial ORR 57.
- 2023Trial resultinnovaTV 301 / ENGOT-cx12 / GOG-3057innovaTV 301 / ENGOT-cx12 / GOG-3057 reported
OS 11.
- 2023MilestoneinnovaTV 301 / ENGOT-cx12 / GOG-3057innovaTV 301 and BEATcc positive
A milestone in how this cancer is treated.
September 2021 · 1
2021 · 4
- 2021Trial resultEMPOWER-Cervical 1 / GOG-3016 / ENGOT-cx9EMPOWER-Cervical 1 / GOG-3016 / ENGOT-cx9 reported
OS 12.
- 2021Trial resultKEYNOTE-826KEYNOTE-826 reported
OS 26.
- 2021MilestoneKEYNOTE-826KEYNOTE-826: pembrolizumab with chemotherapy extends median survival to 26.4 months
A milestone in how this cancer is treated.
- 2021MilestoneTisotumab vedotinTisotumab vedotin accelerated approval; EMPOWER-Cervical 1 positive for cemiplimab
A milestone in how this cancer is treated.